Episode Details

Back to Episodes

Cost of new Alzheimer's drug could put it out of reach for many in Australia

Published 1 year, 9 months ago
Description
The development of the first drug in 30 years that modifies the disease - and not just the symptoms - of the most common form of dementia has given hope to patients. The drug Lecanemab is now undergoing a regulatory approval process in Australia and other countries in the world, but its exorbitant cost means few will be able to access it.
Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us